Skip to main content

United States News All stories

Every story in this section, newest first — page 142 of 373.

Grafa

Merck gains FDA approval for Keytruda plus Trodelvy in first-line TNBC

Merck (NYSE:MRK) announced that the U.S. Food and Drug Administration approved KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy (sacituzumab govitecan-hziy), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (CPS ≥10).

Read more: Merck gains FDA approval for Keytruda plus Trodelvy in first-line TNBC